Odonate Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ODTC research report →
About the company
Odonate Therapeutics, Inc. , a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug.
- CEO
- Kevin C. Tang
- IPO
- 2017
- Employees
- 137
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $8.05B
- P/E
- 3227.62
- P/S
- 0.00
- P/B
- 218.64
- EV/EBITDA
- 846.16
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 7.01%
- ROIC
- -0.57%
- Revenue
- $0 · 0.00%
- Net Income
- $7.33M · -82.94%
- EPS
- $6.82 · -99.98%
- Op Income
- $-817,000
- FCF YoY
- 386.91%
- 52W High
- $358000.00
- 52W Low
- $22005.00
- 50D MA
- $150188.00
- 200D MA
- $139977.00
- Beta
- 0.40
- Avg Volume
- 0
Get TickerSpark's AI analysis on ODTC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ODTC coverage
Recent articles, reports, and earnings notes.
No research on ODTC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ODTC report →Similar companies
Peers in the same neighborhood.